Axim Biotech Enters Canada Through Partnership With Revive Therapeutics

New York-based AXIM Biotechnologies (OTC: AXIM), a cannabinoid R&D firm focusing on delivery systems, announced in late August it signed an exclusive distribution and license agreement with Revive Therapeutics Ltd. (TSX: RVV) (OTC: RVVTF), a specialty cannabis R&D company, to begin selling AXIM’S proprietary, CBD-containing nutraceutical product throughout Canada.

According to Deloitte, the legal cannabis industry in Canada could surge by 58% and generate over $4 billion in sales in its first year.

Revive will seek regulatory approval for AXIM’s proprietary, controlled-release chewing gum containing hemp oil-derived CBD. Revive will also have a minimum purchase amount annually, which increases each year for the term of the agreement.

“We…hope this will create a new revenue stream for both companies and fill a void in quality, tested and proven CBD products for consumers there,” said George E. Anastassov, CEO of AXIM.

In its natural form, cannabinoids are lipophilic, not water-soluble and tend to stick to the chewing gum matrix, diminishing effective release. Microencapsulation makes cannabinoids soluble and increases the bioavailability of CBD.

AXIM’s flagship products include MedChew Rx®, a combination CBD/THC gum that will undergo clinical trials for the treatment of multiple sclerosis; MedChew® Dronabinol which will undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; and CanChew RL, which will undergo clinical trials for treatment of restless leg syndrome.

Revive Therapeutics Ltd. (TSX:RVV) (OTC:RVVTF) is a specialty cannabis company focused on the R&D and commercialization of novel cannabinoid-based products and therapies.

Source Axim press release

Axim Biotech Enters Canada Through Partnership With Revive Therapeutics

About Cannin Investment Group: Your Pot Stocks Experts

Cannin is your trusted resource for pot stocks. Our global team of experts evaluates all emerging pot stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best pot stock investments for 2020.

Use Cannin as your resource for:

Is it too late to invest in pot stocks? No! This is the perfect time to invest.

Market analysts expect the legal cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in pot stocks is now. Are you looking to buy stock in pot companies for 2020? Interested in emerging penny pot stocks? Looking for the best Canadian pot stocks to invest in? We can help.

Are you interested in pot stocks like Curaleaf, Trulieve, Aurora Cannabis, or Canopy Growth?

Predict price movements of pot stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
108% Backtested since 2012

We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best pot stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks to Invest In

Axim Biotech Enters Canada Through Partnership With Revive Therapeutics